⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17772383 | 0.77 | — | — | |
| SCHEMBL21244492 | 0.73 | — | — | |
| SCHEMBL21438551 | 0.69 | — | — | |
| SCHEMBL21622029 | 0.69 | — | — | |
| SCHEMBL469208 | 0.69 | — | — | |
| SCHEMBL1751722 | 0.69 | — | — | |
| SCHEMBL26588779 | 0.69 | — | — | |
| SCHEMBL1752170 | 0.69 | — | — | |
| SCHEMBL1751721 | 0.69 | — | — | |
| SCHEMBL19135521 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4707277-A1 | NOVEL HETEROCYCLIC AMINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Daewoong Pharmaceutical Co., Ltd. (KR) | 2026-03-11 | — | — | EP | disclosed |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| EP-4702025-A1 | BICYCLIC HETEROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2026-03-04 | — | — | EP | disclosed |
| EP-4630406-A1 | AMIDE COMPOUNDS AS ACTIVATORS OF THE POTASSIUM CHANNELS KV7.2/KV7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS | ANGELINI PHARMA S.P.A. (IT) | 2025-10-15 | — | — | EP | disclosed |
| WO-2025129135-A2 | COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250171469-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-05-29 | — | — | US | disclosed |
| US-12304897-B2 | 15-PGDH inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2025-05-20 | — | — | US | disclosed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| CN-112261970-B | 3- (5-Hydroxy-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and their use in the treatment of IKAROS family zinc finger 2 (IKZF 2) dependent diseases | 诺华股份有限公司 | 2025-02-07 | — | — | CN | disclosed |
| WO-2025010314-A1 | UREA-CONTAINING AGONISTS OF OREXIN RECEPTOR TYPE 2 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-01-09 | — | — | WO | disclosed |
| US-20150283134-A1 | Benzamides | MINDIMMUNE THERAPEUTICS, INC. | 2015-10-08 | — | — | US | disclosed |
| EP-2906546-A1 | BENZAMIDES | H. Lundbeck A/S (DK) | 2015-08-19 | — | — | EP | disclosed |
| US-9102591-B2 | Benzamides | H. LUNDBECK A/S (DK) | 2015-08-11 | — | — | US | disclosed |
| US-9102591-B2 | Benzamides | H. LUNDBECK A/S (DK) | 2015-08-11 | — | — | US | disclosed |
| US-9102591-B2 | Benzamides | H. LUNDBECK A/S (DK) | 2015-08-11 | — | — | US | disclosed |
| WO-2014057078-A1 | BENZAMIDES | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | WO | disclosed |
| US-20140107340-A1 | Benzamides | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | US | disclosed |
| US-20140107340-A1 | Benzamides | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | US | disclosed |
| US-20140107340-A1 | Benzamides | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | US | disclosed |
| WO-2014057078-A1 | BENZAMIDES | H. LUNDBECK A/S (DK) | 2014-04-17 | — | — | WO | disclosed |